Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   833 Trials   24825 News 


«12...56789101112131415...441442»
  • ||||||||||  Journal:  The mechanism of EGF in promoting skeletal muscle post-injury regeneration. (Pubmed Central) -  Jun 12, 2025   
    EGF regulates the activities of p38-MAPK and PI3K/AKT/mTOR signaling pathways through the Epidermal Growth Factor Receptor (EGFR), thereby promoting the proliferation and differentiation of myoblasts. This finding will support the treatment of skeletal muscle injury, which is of great value in resolving muscle health problems such as muscular atrophy and sarcopenia.
  • ||||||||||  Journal:  Impact of sarcopenia and obesity on skeletal muscle size, gene expression, and mitochondrial function. (Pubmed Central) -  Jun 12, 2025   
    HFD-induced obesity impacted the muscle transcriptome differently in the muscles of young and aged mice, indicating that obesity can change altered gene expression with age. Our findings suggest that the presence of obesity can both compound and counteract age-associated changes to muscle mass, gene expression, and mitochondrial function.
  • ||||||||||  Review, Journal:  The emerging role of miRNAs in biological aging and age-related diseases. (Pubmed Central) -  Jun 12, 2025   
    We then explore the challenges of translating miRNA-based approaches from preclinical promise to clinical utility, emphasizing the need for trial-level validation to correlate miRNA profiles with clinically meaningful, patient-centred endpoints. By consolidating these findings, this article puts miRNAs forward as a pivotal mechanism in geroscience, offering a novel framework to mitigate ageing-related multimorbidity and bridge the gap between lifespan and healthspan.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Effect of Sarcopenia in Stroke Patients (clinicaltrials.gov) -  Jun 11, 2025   
    P=N/A,  N=83, Completed, 
    Lower SI is independently associated with AVSc in CAD patients and was also associated with adverse cardiovascular events and mortality in CAD patients with AVSc. Trial primary completion date: Jun 2024 --> Dec 2024 | Recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2024
  • ||||||||||  Review, Journal:  Role of microRNAs in Osteosarcopenic Obesity/Adiposity: A Scoping Review. (Pubmed Central) -  Jun 11, 2025   
    Despite the limitations of this review, the findings indicate that miRNAs could serve as promising biomarkers and therapeutic targets for managing OSO/OSA. These results suggest that targeted interventions, such as resistance training and lifelong exercise, may effectively influence miRNA expression, potentially alleviating the impacts of OSO/OSA.
  • ||||||||||  Journal:  Obesity paradox role in the immunosuppressive treatment of hepatocellular carcinoma. (Pubmed Central) -  Jun 11, 2025   
    Obesity's role in anti-programmed cell death protein-1 therapy appears could have a benefit, while its effects on other treatments, such as anti-vascular endothelial growth factor therapy, may reduce efficacy. Further research is needed to explore how obesity influences the effectiveness of other most common immunotherapies like nivolumab, pembrolizumab, and bevacizumab, and whether weight loss as well as weight-loss related sarcopenia impacts these benefits.
  • ||||||||||  Review, Journal:  Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass. (Pubmed Central) -  Jun 11, 2025   
    Management strategies for SMA include resistance training, aerobic exercise, and nutritional support (e.g., high-protein diets, vitamin D, and omega-3 fatty acids), which are essential for mitigating skeletal muscle loss and improving outcomes. However, pharmacological agents that target the muscle and liver (such as glucagon-like peptide-1 receptor agonists) show promise but have not yet been approved for the treatment of MASLD.
  • ||||||||||  Biomarker, Journal:  Association of Alzheimer's Disease Blood Biomarkers With Sarcopenia Incidence and Progression: A 12-Year Population-Based Study. (Pubmed Central) -  Jun 10, 2025   
    Our study, unique for its long follow-up duration, explores the relationship between sarcopenia and neurodegeneration biomarkers, highlighting the role of p-tau181 and NfL in the progression of the condition. These biomarkers could potentially serve as indicators for the early detection of sarcopenia, particularly in older adults and males, offering insights that may contribute to personalized screening and targeted interventions.
  • ||||||||||  New trial, Real-world evidence:  OsBONE: The Oswestry Metabolic BONE Cohort (clinicaltrials.gov) -  Jun 10, 2025   
    P=N/A,  N=4200, Not yet recruiting, 
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Impact of denosumab on muscle health in older adults in long-term care. (Pubmed Central) -  Jun 9, 2025   
    These biomarkers could potentially serve as indicators for the early detection of sarcopenia, particularly in older adults and males, offering insights that may contribute to personalized screening and targeted interventions. Our study found that in older adults in LTCCs, denosumab did not significantly enhance muscle health indices.